Background/Aims: Early metastasis plays a pivotal role in tumor-caused death in gallbladder cancer (GBC) patients. Increasing evidence suggest that miR-143-5p is an active player involved in cancer metastasis and a potential therapeutic target. However, its role in the development of GBC cells remains unclear. The aim of this study is to reveal the inhibiting effects of miR-143-5p on the proliferation and metastasis in GBC. Methods: Quantitative real-time PCR were used to investigate miR-143-5p and its target HIF-1α mRNA levels. Protein expression was measured by immunohistochemistry and western blot. The function and regulation mechanism of miR-143-5p was confirmed by MTS, colony formation, wound healing, transwell, and luciferase reporter assays. Results: miR-143-5p was first found significantly reduced in GBC tissues compared with corresponding noncancerous gallbladder tissues. In addition, miR-143-5p deficiency correlated well with larger tumor size, advanced TNM stage, and poorer survival rate. In vitro, miR-143-5p addition dramatically suppressed GBC cells proliferation, migration and invasion, whereas miR-143-5p antisense led the opposite effects. Further elucidating the molecular mechanism inside, we found miR-143-5p exerted its inhibitory function through downregulating the expression of HIF-1α, which further reduced Twist1 and impeded epithelial-mesenchymal transition (EMT). Conclusions: Altogether, our studies identified a novel regulator, miR-143-5p, implicated in GBC prognosis through targeting HIF-1α/EMT related signaling pathway, which could serve as a biomarker and therapeutic target for GBC.
MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1α in Gallbladder Cancer
determining the concentration and A260/A280 absorbance ratio in Nanodrop 8000 spectrophotometer (Thermo Fisher Scientific, USA), total RNA was reverse-transcribed with Reverse Transcriptase M-MLV kit (Invitrogen). The expression of mRNA and miRNA were analyzed by using SYBR Premix Ex Taq (Takara, Japan) and conducted Q-PCR on the Applied Biosystems ViiATM 7 Real-Time PCR System (Applied Biosystems, USA). All Q-PCR reactions were done in triplicate. The U6 RNA or GAPDH were used as the endogenous controls, and the 2 -ΔΔCT equation was used to calculate the relative quantification of mRNA and miRNA [23] .
Cell transfection HIF-1α expression plasmid was generated by insertion of the CDS of HIF-1α into a pcDNA 3.1 vector (Invitrogen). The mimic miR-143-5p, mimic control, antisense miR-143-5p and antisense control were purchased from GenePharma (China). GBC cells were seeded into 6-well plates, and then transfected with HIF-1α overexpression vector or empty vector, mimic miR-143-5p or mimic control, and antisense miR-143-5p or antisense control by using lipofectamine 2000 (Invitrogen) according to the protocols for 48h.
Protein extraction and western blot analysis
Total protein was extracted from the GBC cells using RIPA lysis buffer supplemented with PMSF and proteinase inhibitor cocktail. The protein concentration was measured by using BCA assay. Equivalent protein of each group were separated by SDS-PAGE and transferred onto a PVDF membranes (Millipore, USA), and then the blots were blocked in a solution of 5% skimmed milk, Tris-bufferred saline with 0.05 % Tween 20 (TBST) for 2 h at room temperature. Target protein was probed with primary antibodies overnight at 4 °C and horseradish peroxidase-conjugated secondary antibodies at room temperature for 2h. Protein bands were visualized with enhanced chemiluminescence reagents (Millipore) in ChemiDoc MP chemiluminescence system (Biorad, USA). Antibodies against HIF-1α (1:300, sc-13515, Santa Cruz), VEGF (1:500, No.9698, Cell Signaling Technology), TWIST1 (1:500, sc-6070, Santa Cruz), β-catenin (1:500, sc-7963, Santa Cruz), Vimentin (1:1000, sc-53464, Santa Cruz), E-cadherin (1:500, SAB4503751, Sigma), Ki-67 (1:1000, No.9449, Cell Signaling Technology), PCNA (1:1000, No.2586, Cell Signaling Technology), and β-actin (1:2000, A5316, Sigma) were purchased.
Immunohistochemistry (IHC) assays
FFPE tissue samples were sectioned into 4 μm thick sections for IHC by using a standard immunestaining protocol, and stained by antibodies against HIF-1α (1:50, sc-13515, Santa Cruz), Ki-67 (1:100, sc-6070, Santa Cruz), TWIST1 (1:50, sc-6070, Santa Cruz), β-catenin (1:50, sc-7963, Santa Cruz), Vimentin (1:100, sc-53464, Santa Cruz), E-cadherin (1:50, SAB4503751, Sigma). After routinely deparaffinization by treating with xylene and rehydrated in gradient ethanol solution, sections were incubated with citrate buffer solution at 100 °C for 1 min for antigen retrieval. Slides were then permeabilized in 0.1% Triton X-100, and incubated overnight at 4 °C with primary antibody mentioned above. Subsequently, the slides were incubated with secondary antibody at 37 °C for 1h. Finally, 3,3-diaminobenzidine tetrahydrochloride was used as the colorizing reagent, and hematoxylin was used to counter stain nuclei. The stained sections were photographed by using light microscopy equipped with camera (Olympus, Japan).
Dual-luciferase reporter assay The 3'-UTR sequence of HIF-1α containing the predicted miR-143-5p targeting site (WT: ACUGCAC) and the mutated 3'-UTR sequence within the predicted target site (MU: AGUGCAC) was synthesized and cloned into a pmirGLO Dual-Luciferase miRNA Target ExpressionVector (Promega). The luciferase reporter assay was performed by the Dual-Luciferase Reporter Assay System (Promega) as previously described [24] .
Colony formation and cell proliferation assay
About 500 cells GBC cells were seeded in 6-well plates and cultured for 14 days. Colony counts were estimated after they fixed with 90% ethanol for 15 min and stained by 0.1 % crystal violet solution for 20 min. For cell proliferation assay, GBC cells (1 × 10 3 ) were seeded in 96-well plates after transfection, and the cell number were assessed by using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-4-sulfophenyl)-2H-tetrazolium (MTS; Promega, USA) in microplate reader.
Wound healing assay and cell invasion assay
For wound healing assay, GBC cells were seeded into 6-well plates and grown to confluence. Wounds were generated by scraping the confluent cell monolayers by using a 200-μL pipette tip. Cells were extensively rinsed to remove cellular debris with PBS, and then cultured in FBS-free medium. Photomicrographs were taken under a microscope at 0 h and 24 h. The percent migration distance of GBC cells was determined by comparing differences in wound width. The invasion abilities of the GBC cells were detected by using 24-well transwell plate with 8-μm poresize polycarbonate membrane (Corning, USA). GBC cells (2 × 10 4 ) in 100 μL of serum-free medium were seeded to the upper chambers with Matrigel (BD) coated membrane for 36h, while the lower chamber filled with 500 μL medium with 10% FBS. After incubation, the upper side of the filters contained the non-invasion cells were detached using cotton swabs, and then fixed with 90% ethanol for 15 min. The cells in the lower side of filters were stained with 0.1 % crystal violet solution for 20 min. Six random fields of each chamber were photographed and the cells stained by crystal was counted.
Subcutaneous and liver metastasis tumor assay in a nude mouse model
The recombinant plasmid containing CDS of miR-143-5p (pLenti6/V5-GW/ miR-143-5p, Thermo Fisher Scientific) or scrambled miRNA and the packaging plasmids (pLP1, pLP2, and pLP/VSVG) were cotransfected into HEK293FT cells by using Lipofectamine 2000 transfection reagent. After transfection for 72 h, the viruses were harvested and then transduced into NOZ cells with 4μg/ml polybrene (Sigma). The stable transfected cells were selected by 2.5 μg/ml puromycin and validated by immunoblotting. Twelve male BALB/c athymic nude mice (4-weeks-old; 15-25 g) were purchased from the Shanghai Laboratory Animal Center (China), and randomly divided into two groups (6 mice/group). All the nude mice were housed in specific-pathogen-free conditions, and all in vivo experiments strictly performed accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of Shanghai Jiao Tong University. A total 2 × 10 6 NOZ cells stably overexpressed miR-143-5p and scrambled miRNA in 100μl medium were subcutaneously transplanted into the mouse left flank of two groups, respectively. Tumor growth curve was measured with a caliper every 3 days from the 7 th day to 40 th day. Tumor volume analysis was based on the equation: V = (length × width 2 ) /2 [25] On day 40, all the mice were euthanized, and the xenografted tumors were dissected out for weighing, H&E and IHC staining. All the mice livers were also harvested for counting the number of metastases.
Bioinformatics of miR-143-5p target gene
The bioinformatics of miR-143-5p target gene were performed by computer-aided algorithms, TargetScan Release 7.0 (http://www.targetscan.org/vert_71/) and miRDB (http://mirdb.org).
Statistical analysis
All experiments were performed in triplicate. The data were expressed as the mean ± standard error of mean (SEM). Comparisons between two groups were performed with the paired Student's t test or independent Student's t-test (two-tailed). For multiple comparisons, the Tukey-Kramer honestly significant difference was applied following ANOVA. Kaplan-Meier plots and log-rank tests were used for POS analysis. Multivariate analysis was performed using Cox's proportional hazards model. The Pearson χ
2 test was used to analyze the bivariate correlations between miR-143-5p expression and HIF-1α mRNA expression. The association analysis between miR-143-5p expression and clinicopathological features was conducted by using χ 2 test. SPSS 17.0 for Windows was used for all statistical analysis (IBM, USA). P < 0.05 was considered statistically significant.
Results

Lower miR-143-5p expression in GBC and its correlation with clinicopathological features in GBC patients
miR-143-5p was previously found involved in various kinds of tumors [8] [9] [10] [11] [12] [13] , but whether and how it implicated in GBC development has never been investigated. To identify the possible relationship, we first examined miR-143-5p expression in 32 GBC and CNG tissues by Q-PCR. Interestingly, a significantly reduced miR-143-5p expression in GBC tissues compared with matched normal tissues was detected (Fig. 1A) . A lower miR-143-5p in different GBC cell lines (NOZ, GBC-SD, SGC-996) compared with normal gallbladder epithelium cell (GBE) was also observed (Fig. 1B) . For further investigating the relationship between miR-143-5p expression and the clinicopathological features and prognosis, we classified the 82 GBC patients according to their respective miR-143-5p expression level (F) Improved cumulative survival rate observed in patients with reduced miR-143-5p expression. U6 small nuclear RNA was used as an internal control in Q-PCR. * P < 0.05; ** P < 0.01; *** P < 0.001; Bar, SEM; Student's t test. Flow cytometry analysis of cell apoptosis rate in GBC (NOZ, GBC-SD and SGC-996) cells transfected with miR-143-5p mimic, antisense and negative control. * P < 0.05; ** P < 0.01; Bar, SEM; Student's t test. 1C) , and several clinicopathological related markers and postoperative survival were analyzed simultaneously. Interestingly, higher miR-143-5p expression correlated well with a smaller tumor size and lower TNM stage ( Fig. 1D-1E , Table 1 ). A significantly improved postoperative cumulative survival rate was also detected with elevated miR-143-5p expression (Fig. 1F) . We then evaluated whether miR-143-5p could serve as an independent prognostic factor by performing univariate and multivariate analyses using the Cox's proportional hazards model. The results showed that miR-143-5p level and TNM stage as independent prognostic factors for these GBC patients (Table 2) . Taken together, these findings indicate that reduced miR-143-5p expression may play an important role in the development and progression of GBC.
Elevated miR-143-5p expression inhibited GBC cells proliferation and metastasis
For further elucidating the effect of miR-143-5p in GBC progression, miR-143-5p mimic (Mimic-miR-143-5p) and miR-143-5p antisense (As-miR-143-5p) were used in GBC cell lines (NOZ, GBC-SD and SGC-996) for altering miR-143-5p expression. MTS and colony formation assays were used for evaluating the effects of miR-143-5p on cell proliferation, wound healing and transwell assays were taken for detecting migration capacity. Consistent with previous clinical studies suggesting a tumor suppressor of miR-143-5p, NOZ, GBC-SD and SGC-996 transfected with miR-143-5p mimic manifested a remarkably lowered proliferation rate compared with cells transfected with negative controls ( Fig. 2A-2B ). Otherwise reducing miR-143-5p expression with amiR-143-5p antisense addition accelerated the proliferation capacity of GBC cell lines ( Fig. 2A-2B) . Furthermore, plate clone forming experiments also exhibited a clone formation inhibition effect with miR-143-5p mimic treatment and a favorable effect with miR-143-5p antisense addition (Fig. 2C) .
The effects of miR-143-5p on cell migration and invasion were also analyzed. According to the results of the wound healing assay, GBC cells transfected with miR-143-5p mimic had a wider interval than the control and more narrow interval in miR-143-5p antisense treatment group (Fig. 3A-3B ). Transwell assay showed that the percentage of migrated cells was significantly lower in GBC cells transfected with miR-143-5p mimic and higher in cells transfected with miR-143-5p antisense (Fig. 3C-3D) . However, miR-143-5p has no effect on apoptosis of GBC cells (Fig. 2D) . These results indicate that miR-143-5p could effectively suppress the growth, migration and invasion of GBC cells in vitro.
HIF-1α is a potential target of miR-143-5p
For further identifying how miR-143-5p influenced GBC cells behavior, target prediction programs were utilized for prediction of the possible target genes of miR-143-5p. HIF-1α, was eventually found to be a potential candidate target. For verifying this regulating mechanism truly existed, the 3'-UTR of HIF-1α, which was predicted could be interacted with miR-143-5p, was cloned into pGL3.0 luciferase reporter vector (Fig. 4A) . miR-143-5p mimic overexpression significantly inhibited wild type HIF-1α 3'-UTR luciferase activity. However, this regulatory effect was disappeared when a mutant 3'-UTR of HIF-1α, of which the miR-143-5p binding site was mutated. (Fig. 4B) . In addition, miR-143-5p mimic addition decreased HIF-1α mRNA and protein levels in GBC cells, while inhibition of endogenous miR-143-5p increased HIF-1α mRNA and protein expression (Fig. 4C-4D) . Pearson's correlation scatter plot of HIF-1α mRNA and miR-143-5p expression in GBC tumors. U6 small nuclear RNA and GAPDH were used as an internal control in Q-PCR. The experiments were repeated three times. * P < 0.05; ** P < 0.01; *** P < 0.001; Bar, SEM; Student's t test.
We then examined HIF-1α expression in 36 cases of GBC tissues and CNG tissues. Elevated HIF-1α mRNA and protein expression were found in GBC tissues in significantly by using Q-PCR and IHC staining (Fig. 4E-4F) . Also, we assessed the expression of HIF-1α in different GBC cells and GBE cells, and found HIF-1α had a relatively high level in GBC cells (Fig. 4G ). An inverse relationship was found between miR-143-5p and HIF-1α expression in GBC tumor samples (Fig. 4H) .
For verifying whether the tumor inhibitory role of miR-143-5p was HIF-1α dependent, GBC cells with miR-143-5p overexpression were then transfected HIF-1α. As expected, HIF-1α overexpression attenuated the anti-tumor role of miR-143-5p, as shown by increased GBC cell proliferation, migration and invasion ( Fig. 5A-5G; Fig. 6A-6D ). Taken together, these data suggest that miR-143-5p may suppress GBC cell proliferation and metastasis by targeting HIF-1α.
miR-143-5p can represses the expression of EMT and angiogenesis marker
EMT has been considered to be a key factor in regulating tumor invasion and metastasis in many cancers, including GBC. During EMT, epithelial cells lose expression of epithelial markers (E-cadherin, N-cadherin, and fibronectin) and acquire a mesenchymal marker (Vimentin) induced by EMT related-transcription factor (β-catenin and TWIST1), resulting in promoting tumor invasion and metastasis [26] . Vascular endothelial growth factor (VEGF) is an important angiogenesis marker, which plays a key role in cancer cell proliferation. Consistently, in our GBC tumors, accompanied with increased Ki-67 + cells (a cell proliferative marker), high-TNM stage GBC tumors also manifested reduced epithelial marker E-cadherin and increased mesenchymal markers vimentin expression (Fig. 7A) . Interestingly, we also found that tumors with lower miR-143-5p expression or higher HIF-1α expression always manifested decreased epithelial marker E-cadherin expression and increased mesenchymal marker vimentin expression, Twist1 expression, and angiogenesis marker VEGF expression (Fig. 7B-7C ). Ki-67 + and PCNA + cells were also elevated in GBC tumors with lower miR-143-5p expression (Fig. 7D) . In addition, we detected the mRNA and protein levels of EMT markers, EMT-related transcription factor, and angiogenesis marker in paired transfected miR-143-5p mimic or miR-143-5p antisense GBC cells. We found that miR-143-5p overexpression decreased β-catenin, Twist1, vimentin and VEGF expression levels, and otherwise increased E-cadherin expression. On the contrary, miR-143-5p inhibition had the opposite effect (Fig.  7E-7H) . These results support a role for miR-143-5p in modulating EMT process and cancer cell proliferation for GBC progression.
miR-143-5p inhibit the growth and liver metastasis in mouse models
For further analyzing the GBC tumor inhibitory role of miR-143-5p in vivo, GBC tumor xenografts model were then used to determine the functional roles of miR-143-5p in Fig. 6 . HIF-1α are involved in the role of miR-143-5p in regulation of GBC cell migration and invasion ability. (A-B) Representative images and quantification of GBC cell migration and invasion activity, as determined by wound healing assay after transfection miR-143-5p mimic and HIF-1α. (C-D) Representative images (C) and quantification (D) of GBC cell migration and invasion activity, as determined by transwell assay after transfection miR-143-5p mimic and HIF-1α. All the experiments were repeated three times. * P < 0.05; ** P < 0.01; Bar, SEM; Student's t test.
controlling tumor growth and metastasis. After being implanted subcutaneously into male nude mice, NOZ cells stably expressing miR-143-5p (average tumor weight of 420 ± 57 mg) showed slower tumor growth rates than controls (average tumor weight of 1190 ± 136 mg) (Fig. 8A-8C) . Strikingly, NOZ cells with miR-143-5p overexpression exhibited significantly reduced liver metastasis rate (Fig. 8D-8E ). Ki-67 and PCNA staining of xenografts showed an average 29% and 55% reduction of Ki-67 + and PCNA + cells in the miR-143-5p overexpression group compared with control group (Fig. 8F-8G) . Moreover, miR-143-5p overexpression xenografts showed reduced HIF-1α, VEGF, β-catenin, vimentin and Twist1 staining, and otherwise epithelial markers E-cadherin was increased (Fig. 8G) . These results from GBC xenograft mouse models provide further support tumor inhibitory role of miR-143-5p.
Discussion
GBC is a malignant cancer with very poor prognosis for its high metastasis propensity at an early time [27] . But the mechanism underlying its high proliferation rate and easy metastasis were still poorly understood. Cumulatively evidence indicated miRNA play a crucial role in the tumor pathophysiology by directly regulating vital oncogene or tumor suppressor [28, 29] + and PCNA + cell rate in high and low miR-143-5p expression groups. (E-H) Q-PCR and western blot analysis of EMT and angiogenesis markers (E-cadherin, vimentin, Twist1, β-catenin, and VEGF) mRNA and protein levels in GBC cells after transfection miR-143-5p mimic or antisense. GAPDH were used as an internal control in Q-PCR. All the experiments were repeated three times. * P < 0.05; ** P < 0.01; *** P < 0.001; Bar, SEM; Student's t test.
that miR-143-5p can inhibit cell cycle and epithelial-mesenchymal transition signaling by targeting STAT3 in esophageal squamous cell carcinoma [8] . In addition, miR-143-5p can produce a significant growth inhibitory effect by directly targeting COX-2 in gastric cancer [30] . miR-143-5p can also suppress bladder cancer cell proliferation through degrading vital oncogene KAS in tumorigenesis [31] .
In this study, Q-PCR results from 36 cases of GBC tissues and CNG tissues found a lower miR-143-5p expression in GBC. Besides, we demonstrated miR-143-5p lower expression was also associated with large tumor size, late TNM stage and poor overall survival. To identify the biological function of miR-143-5p, we constructed miR-143-5p knockdown and overexpression GBC cell lines, results showed miR-143-5p knockdown can promote tumor migration, invasion and proliferation, while miR-143-5p overexpression had the opposite effect. In addition to in vivo experiments, miR-143-5p can also inhibit the growth and liver metastasis in mouse model. All the results above suggested miR-143-5p played a tumor suppressor role in GBC progression.
Further, to explore the underlying mechanism how miR-143-5p suppressed tumor progression, we used target prediction programs to predict genes that were possibly targeted by miR-143-5p. Finally, we found HIF-1α was directly targeted by miR-143-5p. Because of the fast rate of cancer cell proliferation, the existing vasculature can not maintain the supply of oxygen. The fast proliferation rate and lacking enough oxygen of supplying cancer cells made low oxygen tension an important hallmark of solid tumors.
The tumor cells adapt to the hypoxic microenvironment mainly via the regulation of hypoxia-inducible factor (HIF) family of transcription factors. HIF-1α, a master regulator of hypoxia, significantly increased in cancer compared with normal tissues. Indeed, HIF-1α activation has been taken as vital prognostic indicator in numerous cancers [32, 33] . HIF-1α regulated genes play crucial roles in the oxygen homeostasis, energy metabolism, angiogenesis and proliferation. Moreover, HIF-1α is also critically important for tumor invasion and metastasis. Liao et al. generated a transgenic mouse model to conditionally delete HIF-1α and results showed HIF-1α deletion can retard tumor growth and suppress pulmonary metastases [34] . EMT transition is a major process of tumor metastasis. In renal clear cell carcinoma, von Hippel-Lindau tumor suppressor (VHL), a well-known negative regulator of HIF-1α, is loss of function. HIF-1α can reduce E-cadherin expression in the VHL-deficient manner [35] . Meanwhile, the mechanisms contributing to HIF-1α activation in cancer are complicated. It can be activated by the argument of tumor hypoxia condition and also be suppressed by lots of cancer suppressor genes. In this study, we found miR-143-5p functioned as a tumor suppressor gene via targeting HIF-1α. Nevertheless, previous studies confirmed HIF-1α played crucial role in GBC progression, assuming miR-143-5p suppressed tumor progression through regulation of HIF-1α. Later studies confirmed this hypothesis. miR-143-5p can directly interact with the 3'-UTR of HIF-1α and decrease its expression. HIF-1α overexpression had a similar effect on migration, invasion and proliferation as miR-143-5p knockdown. Besides, miR-143-5p can reverse the oncogenic effect induced by HIF-1α overexpression. In brief, the results suggested the tumor suppressor role of miR-143-5p was partially dependent on the suppression of HIF-1αvia the direct interaction with its 3'-UTR.
To conclude, our studies showed miR-143-5p was downregulated in GBC tissues and was inversely correlated with the tumor size and clinical TNM stage. Besides, both in vivo and in vitro experiments clarified that enhanced expression of miR-143-5p suppressed proliferation, migration and invasion by targeting HIF-1α. Our experiments identify a new tumor suppressor in GBC and address its mechanism to inhibit tumor progression. Thus, in consideration of its significant value in medical treatment, miR-143-5p may be a promising tumor biomarker for early diagnosis and prognostic indicator. Additionally, it can be taken as a critical therapeutic target and applied to clinical treatment. Further studies are needed to focus on the molecular mechanism concerning the tumor hypoxia. As tumor hypoxia is a complicated network, an in-depth study will help us to figure out the role of miR-143-5p in hypoxia response.
